Cargando…

Eligibility, Clinical Outcomes, and Budget Impact of PCSK9 Inhibitor Adoption: The CANHEART PCSK9 Study

BACKGROUND: The FOURIER (Further Cardiovascular Outcomes Research With PCSK9i [Proprotein Convertase Subtilisin‐Kexin Type 9 Inhibitors] in Subjects With Elevated Risk) trial found a reduction in cardiovascular events in patients with atherosclerotic cardiovascular disease (ASCVD). Our objective was...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ko, Dennis T., Khan, Anam M., Kotrri, Gynter, Austin, Peter C., Wijeysundera, Harindra C., Koh, Maria, Chu, Anna, Jackevicius, Cynthia A., Lawler, Patrick R., Tu, Jack V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6404170/ https://www.ncbi.nlm.nih.gov/pubmed/30571382 http://dx.doi.org/10.1161/JAHA.118.010007

Ejemplares similares

Association of high-density lipoprotein cholesterol with non-fatal cardiac and non-cardiac events: a CANHEART substudy
por: Wijeysundera, Harindra C, et al.
Publicado: (2017)

Adoption of PCSK9 Inhibitors Among Patients With Atherosclerotic Disease
por: Dayoub, Elias J., et al.
Publicado: (2021)

FOURIER & PCSK9 RNAi: Towards enhancing durability and efficacy of PCSK9 inhibitors
por: Hassan, Mohamed
Publicado: (2017)

The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol
por: Seidah, Nabil G.
Publicado: (2017)

The Multifaceted Biology of PCSK9
por: Seidah, Nabil G, et al.
Publicado: (2021)

The effect of PCSK9 immunization on the hepatic level of microRNAs associated with the PCSK9/LDLR pathway
por: Ataei, Sarina, et al.
Publicado: (2023)

PCSK9 Antibodies for the Treatment of Hypercholesterolemia
por: Gouni-Berthold, Ioanna, et al.
Publicado: (2014)

PCSK9 and Atherosclerosis - Lipids and Beyond
por: Shapiro, Michael D., et al.
Publicado: (2017)

An Update on the Role of PCSK9 in Atherosclerosis
por: Yurtseven, Ece, et al.
Publicado: (2020)

Autocrine effects of PCSK9 on cardiomyocytes
por: Wolf, Annemarie, et al.
Publicado: (2020)

Naturally Occurring PCSK9 Inhibitors
por: Adorni, Maria Pia, et al.
Publicado: (2020)

PCSK9 Monoclonal Antibodies: An Overview
por: Kaddoura, Rasha, et al.
Publicado: (2020)

Pleiotropic Effects of PCSK-9 Inhibitors
por: Basiak, Marcin, et al.
Publicado: (2021)

Phage display for targeting PCSK9
por: Ferri, Nicola
Publicado: (2021)

Insight into the Evolving Role of PCSK9
por: Maligłówka, Mateusz, et al.
Publicado: (2022)

Gene Therapy Targeting PCSK9
por: Katzmann, Julius L., et al.
Publicado: (2022)

PCSK9 as an Atherothrombotic Risk Factor
por: Sotler, Tadeja, et al.
Publicado: (2023)

Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly
por: Holla, Øystein L, et al.
Publicado: (2007)

Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblasts
por: Nguyen, My-Anh, et al.
Publicado: (2014)

Trafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal Domain
por: Poirier, Steve, et al.
Publicado: (2016)

LDL‐cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid‐lowering therapy
por: Hamasaki, Masato, et al.
Publicado: (2021)

PCSK9 Inhibitors Reduce PCSK9 and Early Atherogenic Biomarkers in Stimulated Human Coronary Artery Endothelial Cells
por: Zulkapli, Rahayu, et al.
Publicado: (2023)

PCSK9 and triglyceride-rich lipoprotein metabolism
por: Druce, Irena, et al.
Publicado: (2015)

PCSK9 inhibitors in the prevention of cardiovascular disease
por: Latimer, James, et al.
Publicado: (2016)

PCSK9 targets important for lipid metabolism
por: Schulz, Rainer, et al.
Publicado: (2017)

PCSK9 inhibition in high-risk patients
por: Zijlstra, Laurien E., et al.
Publicado: (2019)

PCSK9 Biology and Its Role in Atherothrombosis
por: Barale, Cristina, et al.
Publicado: (2021)

Editorial: PCSK9: Importance in Physiology and Pathophysiology
por: Schulz, Rainer, et al.
Publicado: (2021)

Physical activity to reduce PCSK9 levels
por: Tirandi, Amedeo, et al.
Publicado: (2022)

The PCSK9 Problem: Is it Predictive, Punitive, or Puzzling?
por: Pamir, Nathalie, et al.
Publicado: (2021)

The Anti-Thrombotic Effects of PCSK9 Inhibitors
por: Péč, Martin Jozef, et al.
Publicado: (2023)

PCSK9 and the nervous system: a no-brainer?
por: Jaafar, Ali K., et al.
Publicado: (2023)

Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations
por: Mayne, Janice, et al.
Publicado: (2013)

Serum PCSK9 levels, but not PCSK9 polymorphisms, are associated with CAD risk and lipid profiles in southern Chinese Han population
por: Cai, Gaojun, et al.
Publicado: (2018)

The association between circulatory, local pancreatic PCSK9 and type 2 diabetes mellitus: The effects of antidiabetic drugs on PCSK9
por: Lu, Fengyuan, et al.
Publicado: (2023)

PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
por: Blom, Dirk J, et al.
Publicado: (2016)

Finding inhibitors for PCSK9 using computational methods
por: Zainab, Rida, et al.
Publicado: (2021)

Identification of Secondary Prevention Patients Eligible for PCSK9 Inhibitors Therapy According to the Routine Clinical Practice in Spain
por: Cosin-Sales, Juan, et al.
Publicado: (2022)

Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Deletion but Not Inhibition of Extracellular PCSK9 Reduces Infarct Sizes Ex Vivo but Not In Vivo
por: Schreckenberg, Rolf, et al.
Publicado: (2022)

NAFLD fibrosis score is correlated with PCSK9 and improves outcome prediction of PCSK9 in patients with chest pain: a cohort study
por: Peng, Jia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kjr44i9dtddrch54to50c34lu7